双价CD47免疫毒素靶向治疗T细胞急性淋巴细胞白血病
本研究利用抗DT的毕赤酵母表达系统,开发了基于白喉毒素的双价抗人CD47免疫毒素(bi-CD47-IT),用于靶向治疗CD47阳性肿瘤。该免疫毒素在多种T-ALL细胞系来源和患者来源异种移植小鼠模型中显示出显著体内疗效,可延长荷瘤小鼠中位生存期并有效清除外周血、脾、肝、骨髓、脑和脊髓中的T-ALL原始细胞。在Molt-4 CDX模型中治愈60%荷瘤小鼠,且体外与人红细胞无结合或凝集,在人源化小鼠中仅短暂耗竭人淋巴细胞约4周,未观察到临床不良事件。
要点
- bi-CD47-IT在T-ALL CDX和PDX小鼠模型中显著延长中位生存期并清除多器官T-ALL原始细胞。
- 在T-ALL Molt-4 CDX小鼠模型中,bi-CD47-IT治愈60%的荷瘤小鼠。
- bi-CD47-IT与人红细胞无结合或凝集,在人源化小鼠中10天治疗后短暂耗竭人淋巴细胞约4周,未观察到临床不良事件。
核心结论
- bi-CD47-IT对CD47阳性T-ALL具有显著体内疗效,且与人红细胞无结合或凝集、对人淋巴细胞结合弱,作者认为其是靶向治疗CD47阳性肿瘤的有前景且安全的候选药物。
研究设计与样本
- 本研究利用抗DT的毕赤酵母表达系统开发了基于白喉毒素的双价抗人CD47免疫毒素(bi-CD47-IT),并在多种T-ALL细胞系来源异种移植(CDX)和患者来源异种移植(PDX)小鼠模型中进行体内疗效评价,同时进行体外结合亲和力、血凝试验及人源化小鼠毒性研究。
主要发现
- bi-CD47-IT在多种T-ALL CDX和PDX小鼠模型中显著延长荷瘤小鼠中位生存期,并高效清除外周血、脾、肝、骨髓、脑和脊髓中的T-ALL原始细胞。
- 在T-ALL Molt-4 CDX小鼠模型中,bi-CD47-IT治愈60%的荷瘤小鼠。
- 体外结合亲和力和血凝试验显示bi-CD47-IT与人红细胞无结合或凝集。
- 人源化小鼠毒性研究显示,10天治疗后bi-CD47-IT短暂耗竭人淋巴细胞约4周,未观察到临床不良事件。
- bi-CD47-IT与CD47阳性T-ALL肿瘤细胞有效结合,与人红细胞无结合,与人淋巴细胞结合弱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD47 is overexpressed on the surface of many types of cancer cells, including T-cell acute lymphoblastic leukemia (T-ALL) cells. In this study, we have developed a diphtheria toxin (DT)-based bivalent anti-human CD47 immunotoxin (bi-CD47-IT) for the targeted therapy of CD47+ cancers using a unique DT-resistant yeast Pichia pastoris expression system. Bi-CD47-IT demonstrated compelling in vivo efficacy in multiple T-ALL cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models. Bi-CD47-IT significantly prolonged the median survival of the tumor-bearing mice and highly effectively depleted the T-ALL blast cells in the peripheral blood, spleen, liver, bone marrow, brain, and spinal cord in the T-ALL CDX and PDX mouse models. Bi-CD47-IT cured 60% of tumor-bearing mice in a T-ALL Molt-4 CDX mouse model. Because CD47 is also expressed on normal tissues, including red blood cells and lymphocytes, specificity is a concern. We thus analyzed the in vitro binding avidity and hemagglutination of bi-CD47-IT in human red blood cells, finding no binding or hemagglutination. We further performed a toxicity study of bi-CD47-IT in humanized mice, which showed that bi-CD47-IT transiently depleted the human lymphocytes for ∼4 weeks after the 10-day treatment. No clinical adverse events were observed. As a result, bi-CD47-IT appears to possess the "optimal" binding avidity, with effective binding to human CD47+ T-ALL tumor cells, no binding to human red blood cells, and weak binding to human lymphocytes. We believe that bi-CD47-IT is a promising and safe therapeutic drug candidate for the targeted therapy of CD47+ cancers.
引用
- Ma J, Wang Z, Mintzlaff D, et al. Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood. 2025. PMID: 39561285. doi:10.1182/blood.2024025277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。